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Edward Rockenstein1, Kiren Ubhi1, Margarita Trejo1, Michael Mante1, Christina Patrick1, Anthony Adame1,
Philipp Novak2, Marion Jech2, Edith Doppler2, Herbert Moessler2 and Eliezer Masliah1,3*Abstract
Background: Alzheimer’s Disease (AD) and Fronto temporal lobar dementia (FTLD) are common causes of
dementia in the aging population for which limited therapeutical options are available. These disorders are
associated with Tau accumulation. We have previously shown that CerebrolysinTM (CBL), a neuropeptide mixture
with neurotrophic effects, ameliorates the behavioral deficits and neuropathological alterations in amyloid precursor
protein (APP) transgenic (tg) mouse model of AD by reducing hyper-phosphorylated Tau. CBL has been tested in clinical
trials for AD, however it’s potential beneficial effects in FTLD are unknown. For this purpose we sought to investigate the
effects of CBL in a tg model of tauopathy. Accordingly, double tg mice expressing mutant Tau under the mThy-1
promoter and GSK3β (to enhance Tau phosphorylation) were treated with CBL and evaluated neuropathologically.
Results: Compared to single Tau tg mice the Tau/GSK3β double tg model displayed elevated levels of Tau
phosphorylation and neurodegeneration in the hippocampus. CBL treatment reduced the levels of Tau phosphorylation
in the dentate gyrus and the degeneration of pyramidal neurons in the temporal cortex and hippocampus of the Tau/
GSK3β double tg mice. Interestingly, the Tau/GSK3β double tg mice also displayed elevated levels of Dynamin-related
protein-1 (Drp-1), a protein that hydrolyzes GTP and is required for mitochondrial division. Ultrastructural analysis of the
mitochondria in the Tau/GSK3β double tg mice demonstrated increased numbers and fragmentation of mitochondria in
comparison to non-tg mice. CBL treatment normalized levels of Drp-1 and restored mitochondrial structure.
Conclusions: These results suggest that the ability of CBL to ameliorate neurodegenerative pathology in the tauopathy
model may involve reducing accumulation of hyper-phosphorylated Tau and reducing alterations in mitochondrial
biogenesis associated with Tau.
Keywords: Tau, GSK3β, Drp-1, Neuroprotection, Alzheimer’s disease, TauopathiesBackground
The cognitive deficits in patients with Alzheimer’s Disease
(AD) and Fronto-temporal lobar degeneration (FTLD) are
associated with selective loss of neuronal populations in
the neocortex, limbic system and subcortical nuclei, in as-
sociation with progressive accumulation of the cytoskeletal
protein Tau [1-7]. FTLD is an heterogenous group of neu-
rodegenerative disorders that are characterised by atrophy* Correspondence: emasliah@ucsd.edu
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article, unless otherwise stated.of the frontal and/or temporal lobes [8]. Examples of
FTLD include Pick’s disease (PiD) and corticobasal degen-
eration. In contrast to AD, which presents predominantly
with memory loss, FTLD is associated with changes in
personal and social conduct, behaviour and language dis-
turbances, and often motor symptoms [9]. In FTLD neu-
rodegeneration is associated with either aggregated Tau or
aggregated TAR DNA-binding protein of 43 kDa (TDP-
43), fused-in-sarcoma or yet unidentified proteins in af-
fected brain regions in the absence of overt beta-amyloid
(Aβ) plaques [10].
The mechanisms through which aggregated and hyper-
phosphorylated Tau leads to neurodegeneration in ADntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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that abnormal Tau might mediate neurodegeneration by
dysregulating Dynamin-related protein-1 (Drp-1), which
in turns results in alterations in mitochondria biogenesis
[11]. Moreover, Tau phosphorylation at Ser262 through
PAR-1 contributes to Tau-mediated neurodegeneration
under a pathological condition in which axonal mitochon-
dria are depleted [12,13]. Thus Tau dependent loss of
axonal mitochondria may play an important role in the
toxicity and pathogenesis of AD [12]. Tau also mediates
the neurotoxic effects of Aβ which can promote the mis-
localization of tau to the dendrites [14] and mitochondria
[15]. In contrast, Tau reduction has been shown to ameli-
orate the behavioral and neurodegenerative pathology in
models of AD [16]. Therefore strategies directed at redu-
cing Tau accumulation might be protective for AD
and FTLD.
We have previously shown that in APP transgenic (tg)
mice over expressing the amyloid precursor protein
(APP), CBL reduces synaptic and behavioral deficits
[17-19]. CBL is a peptide mixture with neurotrophic-like
effects that improves cognition in patients with mild to
moderate AD [20-22]. Moreover, a recent double-blind
trial of CBL was demonstrated to improve the activities of
daily living and psychiatric deficits in patients with moder-
ate to moderately severe AD [21]. Several other random-
ized double-blind studies in patients with AD have shown
that CBL is consistently superior to placebo at reducing
cognitive alterations [23-25].
CBL also ameliorates the neurodegenerative path-
ology and accumulation of Tau in a combined APP tg
mouse model injected with AAV2-Tau [26]. We have re-
cently shown that CBL might reduce APP and Tau path-
ology in models of AD by decreasing CDK5 and GSK3β
activity [26]. However, it is unclear whether CBL might
ameliorate the neurodegenerative pathology in models
of FTLD. For this purpose we generated a new cross of
the mutant Tau tg mice expressing human 4 repeat Tau
(4R-Tau), bearing the missense mutations V337M and
R406W, under the mThy-1 promoter [27] with GSK3β
tg mice. The Tau/GSK3β double tg model displays bio-
chemical and neuropathological features reminiscent of
tauopathies including elevated levels of Tau phosphoryl-
ation and neurodegeneration. We found that adminis-
tration of CBL reduces the levels of Tau and ameliorates
the neurodegeneration in this Tau/GSK3β double tg
model and this is accompained by reduced levels of
Drp-1 and mitochondrial pathology associated with Tau.
Results
Neuropathological and biochemical alterations in
Tau/GSK3β tg mice
The parental single Tau mutant tg mice that we use have
been reported to display moderate alterations in tauaccumulation [27], additionally, previous studies have
shown that adding GSK3β enhances the pathology [28],
therefore Tau/GSK3β bigenic mice were generated by
crossing Tau tg mice expressing human Tau under the
mThy-1 promoter with GSK3β tg mice in order to en-
hance tau phosphorylation. These double tg mice were
subsequently used to evaluate the effects of CBL. Immu-
nochemical analysis was performed in order to compare
the expression patterns and distribution of tau and
GSK3β between the single Tau tg and the Tau/GSK3β tg
mice. By western blot levels of total GSK3β (t-GSK3β)
were 3 fold higher in the GSK3β and Tau/GSK3β tg
compared to non-tg and Tau tg mice (Figure 1A, B).
Likewise, levels of phosphorylated GSK3β (p-GSK3β)
were 3-fold higher in the GSK3β and Tau/GSK3β tg
compared to non-tg and Tau tg mice (Figure 1A, B).
GSK3β was phosphorylated at the T-loop tyrosine Y216
which could play a role in forcing open the substrate-
binding site and has been proposed to correlate with
kinase activation. Levels of Total-Tau (t-Tau) were 2–3
fold higher in the Tau tg and the Tau/GSK3β tg mice
compared to non-tg and GSK3β tg (Figure 1A, C).
Levels of phosphorylated Tau (p-Tau, AT8, Ser202/
Thr205) were increased by 40% in the GSK3β tg, by
200% in the Tau tg and by 350% in the Tau/GSK3β tg
compared to non-tg (Figure 1A, C). The levels of p-Tau
were significantly different between the Tau tg and the
Tau/GSK3β tg. Immunocytochemical analysis showed
that in the GSK3β tg and Tau/GSK3β tg mice levels of
GSK3β immunoreactivity were higher in the pyramidal
cell in neocortex, CA1-CA3 and dentate gyrus of the
hippocampus (Figure 1D, E), as well as in neurons in
the basal ganglia and brain-stem (data not shown),
compared to the non-tg controls and Tau tg mice.
These same neuronal populations also displayed in-
creased p-Tau immunoreactivity in the neocortex and
granular cells in the hippocampus with the AT8 anti-
body (Figure 1F, G). The levels of p-Tau were signifi-
cantly higher in the Tau/GSK3β tg compared to the
Tau tg mice (Figure 1F, G).
To further investigate the effects of age on Tau path-
ology in the single and bigenic mice, immunocytochem-
ical analysis with p-Tau (AT8) antibody was performed
in mice at 3, 6 and 12 months of age. The non-tg and
GSK3β tg mice display low levels of p-Tau immunoreac-
tivity at the 3 time points (Figure 2A, B). Compared to
the control, the Tau tg mice displayed a mild increase in
p-Tau at 6 m and 12 m of age (Figure 2A, B). The Tau/
GSK3β tg displayed a mild increase in p-Tau at 3 m and
a robust progressive increase in p-Tau at 6 m and 12 m
of age (Figure 2A, B). Tau/GSK3β tg mice displayed
greater p-Tau compared to single Tau tg mice therefore
for subsequent studies with CBL we compared the ef-
fects on non-tg vs bigenic mice.
Figure 1 Characterization of Tau/GSK3β bigenic mice. (A) Representative immunoblot image for total GSK3β (t-GSK3β), phospho-GSK3β
(p-GSK3β)(Y216), total Tau (t-Tau) and phospho-Tau (p-Tau) levels in the hippocampus of the Tau/GSK3β bigenic mice compared to Tau tg, GSK3β
tg and non-tg mice. Actin was used as a loading control. (B) Analysis of levels of t-GSK3β and p-GSK3β showing 3 fold higher levels in GSK3β
bigenic mice. (C) Analysis of levels of t-Tau and p-Tau (AT8) showing higher levels of p-Tau in bigenic mice compared to Tau tg mice. (D, E)
Immunohistochemical and image analysis of pGSK3β immunoreactivity in the dentate gyrus of the hippocampus (inset) in the non-tg, single tg and
Tau/GSK3β bigenic mice. (F, G) Immunohistochemical and image analysis of p-Tau (AT8) immunoreactivity in the dentate gyrus of the hippocampus
(inset) in the non-tg, single tg and Tau/GSK3β bigenic mice The boxes indicate regions shown at higher magnification in the lower panels. Scale bar in
upper panel = 250 μm, in lower panels = 30 μm. Error bars represent mean ± SEM (n = 6 per group, 6 m/o). *Indicates a significant difference (p < 0.05)
between non-tg and single or bigenic mice analyzed by one-way ANOVA and Dunnett’s post hoc test. # Indicates a significant difference (p < 0.05)
between Tau tg and bigenic mice analyzed by one-way ANOVA and Tukey-Krammer post hoc test.
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in the bigenic mice
Non-tg and bigenic mice were treated for 3 months (be-
ginning at 3 months of age) with CBL and brains were an-
alyzed with p-tau antibodies. Mice were 6 month old at
the time of the analysis. By immunoblot, levels of t-Tau
were elevated in the Tau/GSK3β bigenic mice compared
to the non-tg, no effects of CBL administration on t-Tau
were observed (Figure 3A-D). Likewise levels of p-Tau
species as detected with the AT8 and AT270 antibodies
were increased in the Tau/GSK3β tg compared to non-tg, however in Tau/GSK3β tg mice treated with CBL,
the levels of p-Tau were reduced by 50% compared to
the vehicle-treated Tau/GSK3β tg group (Figure 3A, E).
Immunohistochemical analysis showed that p-Tau im-
munoreactivity was more prominent in the hippocampal
CA1 and dentate gyrus (DG) regions of the Tau/GSK3β
bigenic mice compared to non-tg controls (Figure 3E, F).
Tau/GSK3β tg mice treated with CBL displayed a 40% de-
crease in the levels of p-Tau immunostaining in the hippo-
campus compared to the Tau/GSK3β tg vehicle group
(Figure 3E, F).
Figure 2 Comparison of effects of aging on p-Tau in non-tg single tg and Tau/GSK3β bigenic mice. (A) Representative images of
immunohistochemical analysis with the p-Tau (AT8) in the neocortex and hippocampus in the non-tg, single tg and Tau/GSK3β bigenic mice at 3, 6 and
12 months of age. (B) Image analysis of optical density in the hippocampus represented as a line graph in the non-tg, single tg and Tau/GSK3β bigenic
mice at 3, 6 and 12 months of age. Scale bar = 250 μm, in lower panels = 250 μm. Error bars represent mean ± SEM (n = 6 per age and genotype).
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bigenic mice
Next we evaluated whether the effects of CBL in the
bigenic mice ameliorated the neurotoxic effects of p-Tau.
For this purpose vibratome sections were immunolabeled
with antibodies against the dendritic marker- MAP2 and
the pan-neuronal marker- NeuN. Vehicle-treated Tau/
GSK3β bigenic mice displayed a significant 25-30% reduc-
tion in MAP2 immunoreactivity in the CA1 region and
the DG molecular layer compared to the vehicle treated
non-tg controls (Figure 4A-C). In contrast, bigenic mice
treated with CBL showed levels of MAP2 immunoreactiv-
ity comparable to non-tg controls (Figure 4A-C). Stereo-
logical analysis of neuronal cell density with NeuN
showed that the vehicle treated Tau/GSK3β bigenic mice
displayed a significant 35-40% reduction in NeuN immu-
noreactivity cells in the CA1 region and the DG granular
cell layer compared to the vehicle treated non-tg controls
(Figure 4D-F). Treatment with CBL ameliorated loss of
NeuN positive cells in the Tau/GSK3β bigenic mice, which
showed cell counts comparable to those observed in the
non-tg controls (Figure 4D-F).
Treatment with CBL reverses alterations in Drp-1 in
Tau/ GSK3β bigenic mice
Previous studies have shown that Tau neurotoxicity might
be mediated by alterations in mitochondrial biogenesis
[11], in this context we examined the levels of Drp-1 a
protein involved in mitochondrial fission and the general
mitochondrial marker Tom40 [29] in the bigenic mice. By
immunoblot analysis, Drp-1 was identified as a single
band at approximately 80 kDa (Figure 5A). Compared to
the vehicle treated non-tg controls, the vehicle treatedTau/GSK3β bigenic mice displayed a significant 35-40% in-
crease in Drp-1 in the cytosolic fraction from hippocampal
homogenates (Figure 5A, B). In contrast, bigenic mice
treated with CBL showed levels of Drp-1 lower than those
detected in the vehicle treated bigenic mice. Moreover,
levels of Drp-1 in the CBL-treated bigenic mice were
slightly below the levels of the non-tg controls (Figure 5A,
B). Level of phosphorylated Drp-1 (p-Drp-1) were higher in
the vehicle-treated Tau/GSK3β bigenic mice in comparison
to vehicle- and CBL-treated non-tg mice (Figure 5C). CBL
treatment significantly decreased expression of p-dDrp-1 in
the Tau/GSK3β bigenic mice, bringing it to levels more
comparable with non-tg controls (Figure 5C).
Immunocytochemical analysis showed that Drp-1 re-
activity was abundant in the neuropil of the cortex. Like-
wise, Tom40 immunoreactivity was most abundant in the
neuropil displaying a fine punctate pattern (Figure 5D).
Compared to the vehicle treated non-tg controls, the
vehicle treated Tau/GSK3β bigenic mice displayed a sig-
nificant 30-35% increase in Drp-1 and Tom40 immuno-
reactivity, while the bigenic mice treated with CBL
showed levels of Drp-1 and Tom40 similar those ob-
served in the non-tg controls (Figure 5D-F).
CBL ameliorates the mitochondrial alterations in
Tau/ GSK3β bigenic mice
Given that the neurodegenerative pathology in the Tau/
GSK3β bigenic mice was concomitant with an increase in
Drp-1, and p-Drp-1, expression and Tom40 puncta, we
next sought to determine whether these alterations corres-
pond to mitochondrial alterations. For this purpose elec-
tron microscopic analysis was performed in hippocampal
sections. Remarkably, compared to the vehicle and CBL-
Figure 3 Immunoblot and immunocytochemical analysis of effect of CBL on Tau in Tau/GSK3β bigenic mice. (A) Representative
Immunoblot image of total-tau (t-Tau), phospho-Tau (p-Tau) at epitopes recognized by the AT8 (Ser202/Thr205) and AT270 (Thr181) antibodies
and actin levels in vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice. (B-D) Image analysis of levels of t-Tau, p-Tau
(AT8) and p-Tau (AT270) respectively in vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice. (E) Immunohistochemical
analysis of p-Tau (AT8) immunoreactivity in the hippocampus of vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice.
Boxes in upper panels are represented at higher magnification in the lower panels. (F) Image analysis of p-GSK3β immunoreactivity in the
hippocampus of vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice. (A, C) Scale bar in upper panels = 250 μm, in
lower panels = 50 μm. (B, D) Error bars represent mean ± SEM (n = 6 per group, 6 m/o). *Indicates a significant difference (p < 0.05) between
vehicle and CBL treated Tau/GSK3β bigenic mice analyzed by one-way ANOVA and Dunnett’s post hoc test.
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Tau/GSK3β bigenic mice showed extensive mitochon-
drial alterations including presence of lamellar intra-
mitochondrial inclusions, incompletely divided and
fragmented mitochondria (Figure 6B, D-F). In contrast,
the mitochondria from the CBL treated bigenic mice
were similar to controls (Figure 6C-F). Consistent with
these observations, image analysis showed that in the
vehicle treated Tau/GSK3β bigenic mice the proportion
of small (less than 0.5 μm), dividing mitochondria with
inclusions was greater when compared to the non-tg
controls, while bigenic mice treated with CBL displayedmitochondrial characteristics similar to non-tg controls
(Figure 6D-E).
Discussion
The present study showed that the Tau/GSK3β double tg
model displays biochemical and neuropathological fea-
tures reminiscent of tauopathies such as elevated levels of
Tau phosphorylation and hippocampal neurodegeneration.
Interestingly, the Tau/GSK3β double-tg mice also display
elevated levels of Drp-1, p-Drp-1, and increased fragmen-
tation of mitochondria accompanied by abnormal divi-
sions and membranous inclusions. In the bigenic mice,
Figure 4 Effect of CBL on neuropathological alterations in Tau/GSK3β bigenic mice. (A) Immunohistochemical analysis of dendritic
pathology as evidenced by MAP2 immunoreactivity in the hippocampus of vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to
non-tg mice. Boxes in upper panels are represented at higher magnification in the lower panels. (B) Quantitative analysis of MAP2 immunoreactivity
in the CA1 region of the hippocampus of vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice. (C) Quantitative
analysis of MAP2 immunoreactivity in the molecular layer (ML) of the dentate gyrus of the hippocampus of vehicle and CBL treated Tau/GSK3β
bigenic mice in comparison to non-tg mice. (D) Immunohistochemical analysis neuronal density as evidenced by NeuN immunoreactivity in the
hippocampus of vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice. Boxes in upper panels are represented at higher
magnification in the lower panels. (E) Quantitative analysis of NeuN immunoreactivity in the CA1 region of the hippocampus the hippocampus
of vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice. (F) Quantitative analysis of NeuN immunoreactivity in the
molecular layer of the dentate gyrus of the hippocampus of vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice.
(A, D) Scale bar in upper panels = 250 μm, in lower panels = 50 μm. (B, C, E, F) Error bars represent mean ± SEM (n = 6 per group, 6 m/o).
*Indicates a significant difference (p < 0.05) between vehicle and CBL treated Tau/GSK3β bigenic mice analyzed by one-way ANOVA and
Dunnett’s post hoc test.
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liorated the neurodegenerative pathology, decreased Drp-
1 and p-Drp-1 expression, and returned mitochondria to
characteristics comparable to non-tg mice.
The mThy1-Tau (V337M and R406W) tg model has
been shown to accumulate soluble p-Tau in the limbic
system and to display spatial learning impairments [27].
The FTDP-17 R406W tau mutation has been described
in an American, a Dutch, and a Japanese family [30-32].
To enhance these deficits we crossed these animals with
an mThy1-GSK3β tg model. This resulted in more wide-
spread accumulation of p-Tau and neurodegeneration in
the hippocampus. The alterations in the Tau/GSK3β
double tg model are comparable to previous reports
using a tg model with conditional overexpression of
GSK3β in forebrain neurons [33,34].
Given the findings with the age dependent analysis
showing that p-Tau accumulation is more abundant in
Tau/GSK3β double tg compared to the single tg mice,
we decided to test the effects of CBL in the bigenic mice.Animals were treated beginning at 3 months of age for
3 months, because at the earlier age group the Tau path-
ology was subtler, becoming progressively worse at 6
and 12 months of age. Therefore, the effects described
in our study represent a preventive trial study for CBL.
Future study will be needed testing the effects of Cere-
brolysin in older Tau/GSK3β double tg compared to sin-
gle Tau tg mice. Moreover, future studies in other
models of Tauopathy such as the Tg4510 are warranted
to further validate our observations.
An additional novel finding of our model was the pres-
ence of widespread mitochondrial pathology and in-
creased Drp-1 expression. This is consistent with recent
studies showing that accumulation of Tau might lead
to neurodegeneration via alterations in mitochondrial
biogenesis [11,35-37]. Drp-1 is known to promote mito-
chondrial fission, consistent with this our ultra-structural
studies showed increased in fragmented mitochondria
with abnormal divisions and inclusions. Remarkably, hy-
peractivation of kinases that phosphorylate Tau such as
Figure 5 Effect of CBL on mitochondrial proteins in Tau/GSK3β bigenic mice. (A) Immunoblot analysis of Drp-1 levels in hippocampal
homogenates from vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice. Actin was used as a loading control.
(B) Quantitative analysis of Drp-1 levels in the hippocampus of vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice.
(C) Quantitative analysis of p-Drp-1 levels in the hippocampus of vehicle and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice.
(D) Immunohistochemical analysis of Drp-1 and Tom40 levels in the hippocampus of vehicle and CBL treated Tau/GSK3β bigenic mice in
comparison to non-tg mice. Arrows indicate immunoreactive mitochondria. (E) Quantitative analysis of Drp-1 levels in the hippocampus of vehicle
and CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice. (F) Quantitative analysis of Tom40 levels in the hippocampus of vehicle and
CBL treated Tau/GSK3β bigenic mice in comparison to non-tg mice. Scale Bars = 5 μm, Error bars represent mean ± SEM (n = 6 per group, 6 m/o).
*Indicates a significant difference (p < 0.05) between vehicle non-tg mice and vehicle-treated Tau/GSK3β bigenic mice and # indicates a significant
difference (p < 0.05) between vehicle and CBL treated Tau/GSK3β bigenic mice analyzed by one-way ANOVA and Dunnett’s post hoc test.
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function leading to mitochondrial alterations [38,39], and
GSK3β has been reported to phosphorylate Drp-1 [40]. In
these bigenic mice, treatment with CBL ameliorated the
neurodegenerative pathology, decreased p-Tau, reduced
Drp-1 and normalized mitochondrial morphology. The
mechanisms through which CBL might achieve these ef-
fects on the bigenic model are not completely clear. We
have previously shown that this neurotrophic peptide mix-
ture is capable of reducing the behavioral deficits in
APP tg mouse model of AD-like pathology [17,18] by
blocking CDK5 and GSK3β [41], resulting in decreased
APP maturation and Aβ biosynthesis [41], increased neu-
rogenesis [42] and synaptic formation [18,41]. Therefore,
it is possible that the effects on Drp-1 observed in the
bigenic mice might be partially mediated by the inhibitory
effects of CBL on CDK5 and GSK3β [43]. Moreover, and
consistent, with the present study, treatment with CBL
in APP tg injected with AAV2-Tau has been reported
to result in a significant amelioration of neurodegenerative
pathology and decreased levels of Tau phosphorylationat critical sites dependent on GSK3β and CDK5 activity
[26]. These results suggest that CBL administration may
have some therapeutic efficacy for the treatment of
tauopathies.
Conclusions
In the Tau/GSK3β double tg model CBL may rescue the
deficits by reducing tau hyperphosphorylation, which in
turn may restore mitochondrial biogenesis. These results
suggest that CBL’s ability to rescue neurodegenerative
pathology in the tauopathy model may involve reducing
accumulation of hyper-phosphorylated Tau and then re-
storing altered mitochondrial biogenesis associated with
Tau. Therefore, CBL might be of potential therapeutical
value in the treatment of certain forms of FTLD.
Methods
Generation of double mutant Tau and GSK3βTg Mice and
CBL treatment
For these experiments, tg mice expressing the human
4R Tau mutated (V337M and R406W) under the control
Figure 6 Ultrastructural analysis of mitochondrial structure in Tau/GSK3β bigenic mice. (A) Ultrastructural analysis of mitochondrial
structure in vehicle-treated and CBL treated non-tg mice. (B) Ultrastructural analysis of mitochondrial structure in vehicle-treated Tau/GSK3β
bigenic mice, boxes in upper panel are shown at a higher magnification in the lower panels. (C) Ultrastructural analysis of mitochondrial structure
in CBL-treated Tau/GSK3β bigenic mice. (D) Quantitative analysis of number of small mitochondria (less than 5 μm) in vehicle and CBL treated
Tau/GSK3β bigenic mice in comparison to non-tg mice. (E) Quantitative analysis of number of dividing mitochondria in vehicle and CBL treated
Tau/GSK3β bigenic mice in comparison to non-tg mice. (F) Quantitative analysis of number of mitochondrial inclusions in vehicle and CBL treated
Tau/GSK3β bigenic mice in comparison to non-tg mice. Scale Bar = 0.5 μm, error bars represent mean ± SEM (n = 6 per group, 6 m/o). *Indicates a
significant difference (p < 0.05) between vehicle non-tg mice and vehicle-treated Tau/GSK3β bigenic mice and # indicates a significant difference
(p < 0.05) between vehicle and CBL treated Tau/GSK3β bigenic mice analyzed by one-way ANOVA and Dunnett’s post hoc test.
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These mice display memory deficits and a moderate
increase in tau phosphorylation in the neocortex and
limbic system. To enhance the Tau pathology the
mThy1-tau tg were crossed with mice over-expressing
human GSK3β under the control of the mThy-1 pro-
moter (mThy1- GSK3β). This line of mice expresses
high levels of constitutive active GSK3β that can hyper-
phosphorylate Tau and other substrates. We have previ-
ously generated similar GSK3β tg mouse lines with both
dominant negative and constitutively active effects [44].
Genomic DNA was extracted from tail biopsies and an-
alyzed by PCR amplification, as described previously
[45]. Transgenic lines were maintained by crossing het-
erozygous tg mice with non-transgenic (non tg) C57BL/
6 × DBA/2 F1 breeders. All mice were heterozygous with
respect to the transgene. A total of 24 Tau/GSK3β tg mice
(3 month (m) old; n = 12 CBL treated and n = 12 saline)and 24 non tg mice (3 m old; n = 12 CBL treated and n =
12 saline) were utilized. A subset of single tg mThy1-Tau
tg and mThy1- GSK3β were utilized as controls. Mice
were injected daily with saline alone or CBL (i.p., 5 ml/kg)
for a total of 3 months. The last injection of vehicle or
CBL was administered 24 hrs before sacrificing the ani-
mals. CBL is a mixture of peptides and amino acids ob-
tained after high quality hydrolyzing and purification
from porcine brain, more information is available at the
web site (http://www.hypermed.com.au/Clinical%20Re-
search/EVER2010_Monograph_screen.pdf ). CBL was a
gift from EverPharma. An additional group of un-
treated non-tg, single tg and bigenic mice were utilized
for analysis of effects of aging at 3, 6 and 12 months of
age (n = 6 per genotype/age group). All experiments de-
scribed were approved by the animal subjects committee at
the University of California at San Diego (UCSD) and were
performed according to NIH guidelines for animal use.
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In accordance with NIH guidelines for the humane treat-
ment of animals, mice were anesthetized with chloral hy-
drate and flush-perfused transcardially with 0.9% saline.
Brains were removed and divided sagitally. The left hemi-
brain was post-fixed in phosphate-buffered 4% parafor-
maldehyde (pH 7.4) at 4°C for 48 hr and sectioned at
40 μm with a Vibratome 2000 (Leica, Germany), while the
right hemibrain was snap frozen and stored at −70°C for
protein analysis.
Immunohistochemical analysis
For this purpose as previously described [26,29], blind-
coded 40 μm thick vibratome sections were immunola-
beled with the mouse monoclonal antibodies against
Drp-1 (1:500, Santa Cruz), Tom40 (1:1000, Santa Cruz),
synaptophysin (presynaptic terminal marker, 1:40,
Chemicon), GFAP (astroglial marker, 1:1000, Chemicon),
p-Tau (AT8, 1:500, Pierce; AT270 1:500, Pierce), t-Tau
(1:500, Dako), t-GSK3β (1:500, Cell Signaling) and p-
GSK3β (GSK3βY216, 1:500, Life Technologies), as previ-
ously described [18,41]. After overnight incubation with
the primary antibodies, sections were incubated with
Texas red or FITC-conjugated horse anti-mouse IgG sec-
ondary antibody (1:75, Vector Laboratories), transferred to
SuperFrost slides (Fisher Scientific) and mounted under
glass coverslips with anti-fading media (Vector). All sec-
tions were processed under the same standardized condi-
tions. The immunolabeled blind-coded sections were
imaged with the laser-scanning confocal microscope
(LSCM, MRC1024, BioRad) and analyzed with the Image
1.43 program (NIH), as previously described [18]. To con-
firm the specificity of primary antibodies, control experi-
ments were performed where sections were incubated
overnight in the absence of primary antibody (deleted) or
preimmune serum and primary antibody alone.
The numbers of NeuN-immunoreactive neurons were
estimated using unbiased stereological methods [46].
Hemi-sections containing the neocortex, hippocampus
and striatum were outlined using an Olympus BX51
microscope running StereoInvestigator 8.21.1 software
(Micro-BrightField). Grid sizes for the striatum, frontal
cortex, and hippocampal CA3 pyramidal layer were:
900 × 900, 800 × 800, and 300 × 300 μm, respectively, and
the counting frames were 40 × 40, 30 × 30, and 50 ×
50 μm, respectively. The average coefficient of error for
each region was 0.9. Sections were analysed using a 100 ×
1.4 PlanApo oil-immersion objective. A 5-μm high disec-
tor, allowed for 2 μm top and bottom guard-zones.
Immunoblot analysis
Briefly, as previously described [47] protein homogenates
from the hippocampus of vehicle and CBL-treated Tau/
GSK3β bigenic mice and non-tg mice were prepared byfractionation into cytosolic and membrane-bound constit-
uents. Twenty micrograms of cytosolic protein per mouse
were loaded onto 4-12% Bis-Tris (Invitrogen) SDS-PAGE
gels, transferred onto Immobilon membranes, washed and
blocked in BSA. After an overnight incubation with anti-
bodies against total (1:1000, Cell Signaling) or p-GSK3β
(Y216, 1:1000, Life Technologies) [33,34], total (1:500,
Dako) and p-Tau AT8, AT270 (1:1000, Pierce) and Drp-1
(1:500, Santa Cruz), membranes were incubated in appro-
priate secondary antibodies, reacted with ECL and devel-
oped on a VersaDoc gel-imaging machine (Bio-Rad,
Hercules, CA). Anti-beta-actin (1:1000; Sigma) antibody
was used to confirm equal loading.
Electron microscopy and immunogold analysis
Briefly [48], vibratome sections were post-fixed in 1% glu-
taraldehyde, treated with osmium tetraoxide, embedded in
epon araldite and sectioned with the ultramicrotome
(Leica, Germany). Grids were analyzed for mitochondrial
morphology [49] with a Zeiss OM 10 electron microscope
as previously described [40]. Electron micrographs were
obtained at a magnification of 25,000X.
Statistical analysis
Analyses were carried out with the StatView 5.0 pro-
gram (SAS Institute Inc., Cary, NC). Differences among
means were assessed by one-way ANOVA with post-hoc
Dunnett’s. Comparisons between 2 groups were assessed
using the two-tailed unpaired Student's t-test. Correlation
studies were carried out by simple regression analysis and
the null hypothesis was rejected at the 0.05 level.
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